The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri… - The Lancet, 2022 - thelancet.com
Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …
the face of European hepatology is changing due to the cure of viral hepatitis C and the …
A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug …
A Radley, E Robinson, EJ Aspinall, K Angus… - BMC health services …, 2019 - Springer
Abstract Background Direct Acting Antiviral (DAAs) drugs have a much lower burden of
treatment and monitoring requirements than regimens containing interferon and ribavirin …
treatment and monitoring requirements than regimens containing interferon and ribavirin …
“Health is on the back burner:” multilevel barriers and facilitators to primary care among people who inject drugs
Background The estimated 2.2 million people who inject drugs (PWID) in the USA
experience significant gaps in preventive healthcare and a high burden of infectious …
experience significant gaps in preventive healthcare and a high burden of infectious …
Accessible hepatitis C care for people who inject drugs: a randomized clinical trial
B Eckhardt, P Mateu-Gelabert… - JAMA Internal …, 2022 - jamanetwork.com
Importance To achieve hepatitis C elimination, treatment programs need to engage, treat,
and cure people who inject drugs. Objective To compare a low-threshold, nonstigmatizing …
and cure people who inject drugs. Objective To compare a low-threshold, nonstigmatizing …
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a …
Background Highly effective direct-acting antiviral drugs provide the opportunity to eliminate
hepatitis C virus (HCV) infection, but established pathways can be ineffective. We aimed to …
hepatitis C virus (HCV) infection, but established pathways can be ineffective. We aimed to …
[HTML][HTML] Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical …
Background Following advances in treatment for hepatitis C (HCV), optimizing linkage to
care and adherence to treatment of people who inject drugs became of pivotal importance …
care and adherence to treatment of people who inject drugs became of pivotal importance …
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
LT Fadnes, CF Aas, JH Vold, RA Leiva… - PLoS …, 2021 - journals.plos.org
Background The standard pathways of testing and treatment for hepatitis C virus (HCV)
infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID) …
infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID) …
Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients
Finding new ways to increase access to hepatitis C (HCV) treatment is integral to reducing
liver diseaserelated deaths and achieving HCV elimination in the Asia-Pacific …
liver diseaserelated deaths and achieving HCV elimination in the Asia-Pacific …
Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington
MA Corcorran, JI Tsui, JD Scott, JC Dombrowski… - Drug and alcohol …, 2021 - Elsevier
Abstract Background Direct acting antivirals (DAAs) have revolutionized management of
hepatitis C virus (HCV), but treatment uptake remains low among persons who inject drugs …
hepatitis C virus (HCV), but treatment uptake remains low among persons who inject drugs …
Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—the practitioner …
Background Since the advent of interferon-free, direct-acting antiviral (DAA) therapies for
hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide …
hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide …